Raymond James started coverage on shares of Gritstone Oncology (NASDAQ:GRTS) in a research note released on Thursday morning, The Fly reports. The firm issued an outperform rating on the stock.
GRTS has been the topic of several other reports. BTIG Research increased their price target on shares of Gritstone Oncology to $31.00 and gave the company a buy rating in a research report on Tuesday, December 11th. HC Wainwright began coverage on shares of Gritstone Oncology in a research report on Thursday, March 7th. They issued a buy rating and a $17.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $22.75.
GRTS stock opened at $10.22 on Thursday. Gritstone Oncology has a 12 month low of $9.66 and a 12 month high of $32.90.
Gritstone Oncology Company Profile
Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.
Featured Article: Insider Trading
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.